Q-omics provides the consensus-scored KDM4E profile across patient tissues and cancer cell-line models. KDM4E expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KDM4E is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, KDM4E RNA expression shows 11,766 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where KDM4E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM4E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM4E survival associations across molecular data types. KDM4E RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM4E RNA expression–survival associations across cancer types. High KDM4E expression shows unfavorable associations in ACC, LUSC and READ, but favorable associations in HNSC, THCA and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KDM4E RNA expression.
This table summarizes KDM4E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KDM4E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM4E shows lower tumor expression in KICH, BRCA, KIRP, STAD, KIRC and THCA. The KICH box plot shows higher KDM4E RNA expression in normal versus tumor tissue (log2 FC = −0.111, t-test p < 0.001).
This table shows molecular features associated with KDM4E in patient tissues and cancer cell lines. In patient samples, KDM4E shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM4E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
